Pharmacy systems providers link up to offer improved prescriber verification
FORT WORTH, Texas — Integrated pharmacy systems provider PDX and Health Market Science, a leading source for health provider data and solutions, have teamed up to improve the accuracy and safety of the prescription verification process.
The two firms unveiled a stepped-up alliance Wednesday that they said will provide pharmacies with real-time prescriber validation solutions when dispensing prescriptions. The new, jointly developed automation solution said both companies “mitigate the risk of submitting an invalid prescriber identifier or submitting a prescription for a state or federally sanctioned prescriber.”
To that end, PDX and HMS will provide “advanced point-of-service compliance solutions” that integrate the PDX Pharmacy System with HMS’ Prescriber MasterFile. It means that pharmacists using PDX software will have instant access to up-to-date information on prescribing physicians, including licensure, professional status, sanctions and Drug Enforcement Administration prescriptive authority.
The result, both companies said, will be an improved and simpler verification of prescriptions as part of the dispensing process. “Each pharmacy transaction is reviewed in real time to determine if the authorizing prescriber’s license and credentials are valid and appropriate for the drug being dispensed,” they noted.
In the future, PDX’s Enterprise Pharmacy System also will be linked to the new verification process, PDX spokesman Todd Whitely reported.
Lending urgency to the effort, PDX president and CEO Jeff Farris said, is “the intense regulatory scrutiny at the state and federal level” over the prescription dispensing process. “We had to make our solution as effective as possible during the filling of a prescription, so pharmacy staff could mitigate risk without compromising customer satisfaction,” Farris explained. “By integrating our systems with the most up-to-date sanctions data available on the market from Health Market Science, we can help our pharmacy customers address the compliance challenges.”
Merck to acquire SmartCells
WHITEHOUSE STATION, N.J., and BEVERLY, Mass. (Dec. 2) Merck announced on Thursday it has inked a deal to acquire an insulin maker.
The drug maker said it has entered a definitive agreement to acquire SmartCells, a company developing a glucose responsive insulin formulation for the treatment of diabetes. Under the terms of the agreement, Merck will acquire all outstanding stock of SmartCells. In return, SmartCells shareholders will receive an upfront cash payment and be eligible to receive clinical development and regulatory milestones for products resulting from the transaction for potential aggregate payments in excess of $500 million, Merck said.
"Maintaining control of blood glucose levels represents a daily challenge for people living with diabetes," said Nancy Thornberry, SVP and head of diabetes and obesity franchise at Merck Research Labs. "Through the acquisition of SmartCells we have obtained innovative technology that may enable us to develop glucose-responsive insulins. If this investigational technology is ultimately approved for use with patients, it could provide an important new therapy for the treatment of diabetes. This holds the potential to significantly impact the treatment of this disease."
The acquisition will expand Merck’s diabetes portfolio, which currently includes Januvia and Janumet.
Oramed announces publication in diabetes journal
JERUSALEM — Oramed Pharmaceuticals, a developer of oral drug delivery solutions, has published an article in the Journal of Diabetes Science and Technology’s November issue describing evaluation of the company’s glucagon-like peptide (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.
GLP-1 and its analogs harbor significant therapeutic potential for management of Type 2 diabetes mellitus through their broad physiological impact on glucose regulation-related mechanisms. To date, these drugs are only available in injectable forms, leading to systemic effects upon administration as well as unsatisfactory patient compliance and adherence.
Oramed has applied its oral drug delivery platform to the GLP-1 analog family of medications. High sugar-content meals were delivered to animals in the presence or absence of ORMD-0901, followed by close monitoring of blood glucose levels. Specific formulations were found to effectively blunt expected glucose surges in both ORMD-0901-treated pigs and canines. The two animal models used for testing the performance of ORMD-0901 indicated retained drug activity when delivered using Oramed’s oral drug delivery platform.
Oramed already has started clinical testing of its ORMD-0901 product to test the formulation’s safety and efficacy in healthy individuals. Further testing and development are expected to significantly contribute to current diabetes control options and success rates.
To view the article abstract, click here.